Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL The fact that there is no document proving any cog improvement for 2-73, demonstrates how desperate Dr Missleading is. More fake news.
Obviously that is a pile of BS. Where does Dr Missleading claim any of this is a possibility, or is he having surrogates spread more of his lies. It would be another illegitimate trial by the fake Dr.
Official Title: A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)
Did this come from Dr Missleading on the side. All documentation says trial will not be concluded until end of March 2021. Guess when they are dealing with a third world country AVXL can buy off anyone.
Estimated Study Completion Date : March 31, 2021
"All that is needed is confirmation of previous results for provisional approval. "
LOL - No speculation, yes hope with a good reason, only thing needed is confirmation of previous results. No safety issues, IV not an issue. You have to hope because there is no, nada, ZERO, published results from a valid trial with 2-73. I hear the sound of desperation, if an when NTRP AD confirmatory trial shows positive results your opinion will again be shown to be erroneous.
All you have is speculation and hope, no results, that speaks for itself. the Dr Missleading hired guns work for money, they have all been involved in bio failures before bet they cant wait to explain why 2-73 failed.
What is Imaginary with 2-73 is the science, it supposedly cures everything it is safe and cheap. There is no evidence that it does anything more than a Placebo pill. Placebos are cheap and safe and have shown efficacy in many diseases also, maybe Dr Missleading can get the Aussies to fast track that.
LOL- Dr Alkon is a real Dr, Dr Missleading is a snake oil salesman, I think Missleading has a patent on lying and paying for stock promotion.
LOL - the only thing 2-73 is close to is becoming a Placebo pill. When the results show that it has the same effect as Placebo. Where is there any study results for 2-73 that it reverses anything?
I think there would be a very good chance for an early approval, given there is no other known treatment to halt or reverse AD. If that happens the MC could be $3-5B until sales ramp up which could take a year or so. If no early approval, then I would not expect more than $1-2B MC until approval or until a BP partnership. I think that the market is getting gun shy of AD trials, so would not expect a MC like AXON.
That would be great, in four weeks all the data should be collected. Allow 4 hours to write up a report and we should have our confirmation. ;)
Final dosing of last patients should be next week. Wonder if they do a press release, or wait for final SIB test in 4 weeks.
It has helped that the SP is back over $5.
It is hard to say what NTRP management would be thinking, but I do not seethe approval of the synthetic being any road block, especially for a BP company. I would think Dr Alkon would like to see the path that gets the drug to market the quickest. I personally think that the route will be a collaboration and licensing agreement.
Understand, not necessarily a "stock" deal, looking for more of a partnership. NTRP my have people that can do it, may just need a big law firm to help hammer something like that out.
Katalyst Securities LLC and Maxim Group LLC. I actually had a call left on my machine from someone from Katalyst. If I would have returned the call probably would have participated.
No, they had an investment banker for the last one, I want a sales/ marketing agreement with prepaid royalties, if they do anything this year.
Yes lets be optimistic. My take is that the longer it takes to get the results out the greater the angst for stockholders. So I guess the smart thing is to be pessimistic. I guess if it gets delayed we could claim that they are data mining as part of a "precision medicine" group hug.
Mid August would be 5 months from last patient first dosing to results. As I posted earlier in the original 2B it was 5 months, so there is precedent for it happening that soon. August is probable the earliest that we see the results. IMO
ITT you may be right, but if they let the BP community know they are looking for a partner once internally they know the results are good. then interested BP companies will contact them and NDA's would be appropriate. We are only talking a matter of a few weeks either way. What would make the most sense to me would be for them to pursue a distribution agreement with a BP partner, with prepaid license fees up front to fund any to market requirements, ie P3/4 etc.
Gotcha. Looking at last time, it was 5 months from final patient first dosing and results reporting. Five months from 13 March is mid August.
There are pluses and minuses for predicting the results date. The biggest plus for 5 months or less is that this trial is simpler, smaller and the team is experienced in processing the results. The only negative I see is how gunshy they will be with giving results before all I's are dotted and It's are crossed.
How to you get July 28. If you go 15 weeks from final patient initial dosing on March 13, I get June 28 as 15 weeks. What am I missing?
NEW YORK, March 13, 2019 /PRNewswire/ — Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that it has initiated dosing in the final patient in the Company’s randomized, double-blind, placebo-controlled, confirmatory Phase 2 clinical...
LOL - they are set up to make Dr Missleading a lot of money at the expense of the stockholders.
Thanks for your analysis and I tend to agree with you. I also think that a factor this time as opposed to the original 2b is that they have more experience with the screening process and they are using the same 29 clinical sites. I do not know how many patients they screen last time but getting 111 out of 211 seems like they had a good response for the trial and could be "fussy" about who they let in.
ROTFLMAO good one.
That's great, having the sperate tracks of severe and moderate should help "confirm" that. To me this should also provide justification for also treating mild patients. Thanks.
Coach, thanks. Without me looking for it. Do we know if the non-men patients more in the moderate or severe tracks.
FBG that is a good point, one can hope that the placebo's dropouts are higher, then you have the issue of accounting for non-completers. Not an expert on what will skew the p-value.
I would think that having the two equal arms, could help in several ways. I would expect more dropouts in the severe areas. What happens to the p-value if there are a lot of dropouts. I am just looking for things that prevent this from being a slam dunk.
Coach, a question I have meant to ask, is what do you see for trial dropouts. Do you think that is why they have sperated moderate and severe into groups.
Still could be latest warrant holders selling into strength tamping down the buys from those coming to the party late.
High volume making it hard to manipulate the stock, well maybe tomorrow. :)
It's pretty easy for most people to figure out. Some of the warrant holders are selling short to cover for investment with a profit. Still a small amount compared to a $3.00 bio stock scam with 5m shares short.
We have announced a partnership with Nemours on FragX, and are working with John Hopkins on MS. When you have partners things become more complicated usually drawing things out. That is also why you don't do BP deals until it's the right time and with the right partner.
It is not pumping when it is based of facts. The majority on here just look at the science, the science that has been created from a valid trial, published and peer reviewed. That has now has a FDA approved confirmatory trial weeks away from completion. How many people know that, I have no clue, but the fewer that currently know the bigger the opportunity. It is almost like insider trading.
That is not sad, that is called opportunity that will be proven one way or another in weeks for NTRP. What is really sad is that it will be years before AVXL has any results, which means another 100k of MB pumps.
How sad is it that with 3 trials under way the AVXL stock is trying to hold $3 per share. Market knows thst they will fail, despite 192,000 MB posts pumping it.
At least you are smart enough to own NTRP, hopefully you are not losing to much on AVXL. Also fully diluted AVXL MC $163m, NTRP 166m.
No evidence that they were adopted or even being used, how many other failed AD trials have the Aussies funded? Sure no one can sweet talk better than Dr Missleading.
LOL - You made my point about Dr Misleading and promoting an AVXL agenda.
"You can't believe everything you read on the internet.
Some people will say anything to further an agenda"
Your documents are as Misleading as Dr Misleading. They were recommendations by a committee, which means that they are not doing it that way but should be. To bad this type of misinformation has not helped AVXL's stock price.